Seven Eight Capital’s Supernus Pharmaceuticals SUPN Stock Holding History

Seven Eight Capital’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-39,655	Closed	-$1.39M	–	724
2019 Q1	$1.39M	Buy	+39,655	New	+$1.48M	0.07%	307
2018 Q4	–	Sell	-14,655	Closed	-$738K	–	701
2018 Q3	$738K	Buy	+14,655	New	+$724K	0.04%	403
2017 Q3	–	Sell	-300	Closed	-$13K	–	606
2017 Q2	$13K	Buy	+300	New	+$10.7K	﹤0.01%	521

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

NPIC

Neumeier Poma Investment Counsel Carmel, California $1.21B AUM 70.48% 1-Year Est. Return

Seven Eight Capital's SUPN Position: Q2 2019 in Review

Seven Eight Capital sold out of Supernus Pharmaceuticals (SUPN) in Q2 2019, closing a stake of 39,655 shares — an estimated $1.39M sold.

Seven Eight Capital first reported a position in SUPN in Q2 2017 and held it in 3 quarters. The position peaked at $1.39M in Q1 2019. 272 funds tracked by Wall St. Rank hold SUPN as of Q2 2019.

Seven Eight Capital reported no remaining Supernus Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Seven Eight Capital sold 39,655 Supernus Pharmaceuticals shares in Q2 2019, an estimated $1.39M.
Seven Eight Capital first reported a position in Supernus Pharmaceuticals in Q2 2017 and held it in 3 quarters.
Seven Eight Capital's Supernus Pharmaceuticals position peaked at $1.39M in Q1 2019.
272 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2019.

Based on Seven Eight Capital's 13F filing for Q2 2019, filed 12 Aug 2019.